Biogenera SpA is pleased to announce a new scientific collaboration with University of Chicago, one of the leading medical institutions in the United States, to advance research in the cure of pediatric patients affected by Neuroblastoma, a rare and aggressive childhood cancer.
This collaboration will involve two world-renowned experts in pediatric oncology, Professor Susan Cohn and Associate Professor Ami Desai, both widely recognized as Key Opinion Leaders (KOLs) in the field of Neuroblastoma research and treatment.
The goal of the partnership is to conduct combined preclinical experiments to further evaluate the precision medicine efficacy of BGA002, the anti-MYCN Biogenera’s proprietary drug, in Neuroblastoma models. These studies will provide new critical insights into the therapeutic potential of BGA002 and its mechanism of action, with the intention to proceed with clinical studies in children that do not respond to conventional therapies.
“We are honored to collaborate with Biogenera on this important project,” said Professor Susan Cohn and Associate òProfessor Ami Desai. “The development of innovative treatments such as BGA002 offers hope for improving outcomes for children affected by neuroblastoma, and we are excited to contribute our expertise to this endeavor.”
This initiative underlines Biogenera’s commitment to innovative research and the development of new solutions for unmet medical needs, with a particular focus on rare pediatric diseases.
English 
Italian